Phio Pharmaceuticals is heading to the 153rd Conference hosted by NIBA, where it will showcase its unique INTASYL® platform, the PH-762 program, and its overall strategic vision.
Featuring an update on its proprietary INTASYL siRNA therapeutic platform and the progress of its lead PH-762 program targeting cutaneous squamous cell carcinoma
Phio Pharmaceuticals Corp. (NASDAQ:PHIO)
Also worth a look: Scofield group tops $160M in Las Vegas real estate sales by Q3 2026 and PHA pushes feds for timely, practical telemedicine prescribing rule.
NIBA offers a valuable setting for sharing Phio’s investment story, which is built on a unique siRNA therapeutic platform aimed at boosting immune-cell activity against solid tumors.”— Robert Bitterman, President and CEO of Phio Pharmaceuticals Corp. KING OF PRUSSIA, PA, UNITED STATES, October 5, 2026 /EINPresswire.com/ — Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology firm creating cancer treatments based on its proprietary INTASYL® siRNA gene-silencing technology, announced today that it has accepted an invitation to present at the National Investment Banking Association’s (NIBA) 153rd Conference, scheduled for October 6-7, 2026, in Fort Lauderdale, Florida.
Phio Pharmaceuticals Corp. is a B2i Digital Featured Company. View the company's comprehensive profile at: https://b2idigital.com/phio-pharmaceuticals
Robert Bitterman, President and Chief Executive Officer, will deliver a presentation covering Phio’s INTASYL® siRNA therapeutic platform, its distinct delivery method, and the company’s strategic path forward. The talk will also include a progress report on PH-762, the company’s lead clinical-stage candidate for cutaneous squamous cell carcinoma (cSCC). Both Robert Bitterman, CEO, and Lisa Carson, CFO of Phio Pharmaceuticals, will attend the event and be available for private meetings to explore topics in greater depth.
“NIBA provides an excellent forum to communicate Phio’s investment thesis based on a differentiated siRNA therapeutic platform designed to enhance immune-cell function in solid tumors with a strong safety profile,” stated Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals.
Presentation Details:
Date: October 7, 2026
Time: 12:40 PM (EDT)
Venue: The Westin Fort Lauderdale Beach Resort, Fort Lauderdale, Florida
Presenter: Mr. Robert Bitterman, CEO and President, Phio Pharmaceuticals
About National Investment Banking Association
The National Investment Banking Association (NIBA) is a nonprofit organization that has been serving the micro-cap and small-cap investment community for close to 50 years. The website for NIBA’s 153rd Investment Conference can be found here: https://nibas-152nd-investment-conference.events.accessnewswire.com/
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio’s INTASYL compounds are designed to boost the body’s immune cells so they can kill cancer cells more effectively. Phio’s lead clinical development program is an INTASYL compound, PH-762, which silences the PD-1 gene implicated in various types of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment option for skin cancers.
For more information, visit the Company’s website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “intends,” “believes,” “anticipates,” “indicates,” “plans,” “expects,” “sugests,” “may,” “would,” “should,” “potential,” “designed to,” “will,” “ongoing,” “estmate,” “forecast,” “target,” “predict,” “could” and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body’s immune cells more effective in killing cancer cells, the potential for PH-762 to present a viable non-surgical alternative for skin cancer, our plans and expectations regarding FDA submissions and related interactions, including our intention to meet with the FDA to discuss potential next steps in the clinical trial design and development of PH-762, our belief that submission of our comprehensive briefing package to the FDA will support the next stage of clinical development of PH-762 and is an important step toward unlocking the PH-762 clinical potential in cutaneous squamous cell carcinoma, our belief that we will work with the FDA as we pursue the next phase of development of PH-762, our belief that activities supporting the next phase of clinical development of PH-762 are expected to be completed during the first quarter of 2027, and statements regarding our clinical strategy, development plans and timelines and other future events.
These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact of future FDA interactions on the development of our product candidates; our ability to work with the FDA; the development of our product candidates, results from our nonclinical, preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors” and in other filings the Company periodically makes with the U.S. Securities and Exchange Commission. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
Media Contact:
David Shapiro
B2i Digital, Inc.
+1 212-579-4844
david@b2idigital.com
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
TikTok
X
Other
PHIO CEO Robert Bitterman to present INTASYL® and PH-762 update at NIBA on Oct. 7.
